TRANDATE HCT Drug Patent Profile

When do Trandate Hct patents expire, and when can generic versions of Trandate Hct launch?

Trandate Hct is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in TRANDATE HCT is hydrochlorothiazide; labetalol hydrochloride. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; labetalol hydrochloride profile page.

Summary for TRANDATE HCT

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	10
DailyMed Link:	TRANDATE HCT at DailyMed

Recent Clinical Trials for TRANDATE HCT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Loma Linda University	N/A
Nebraska Methodist Health System	Phase 4
Wright State University	Phase 4

See all TRANDATE HCT clinical trials

US Patents and Regulatory Information for TRANDATE HCT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-001	Apr 10, 1987		DISCN	No	No
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-004	Apr 10, 1987		DISCN	No	No
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-002	Apr 10, 1987		DISCN	No	No
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-003	Apr 10, 1987		DISCN	No	No

Expired US Patents for TRANDATE HCT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-002	Apr 10, 1987	4,066,755
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-003	Apr 10, 1987	4,066,755
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-001	Apr 10, 1987	4,012,444
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-002	Apr 10, 1987	4,012,444
Glaxosmithkline	TRANDATE HCT	hydrochlorothiazide; labetalol hydrochloride	TABLET;ORAL	019174-004	Apr 10, 1987	4,012,444

International Patents for TRANDATE HCT

See the table below for patents covering TRANDATE HCT around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	280996
Austria	300763
Belgium	704037
Belgium	752892
Canada	932734	PHENYLAMINOETHANOL DERIVATIVES

Supplementary Protection Certificates for TRANDATE HCT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0443983	C00443983/03	Switzerland		PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
0502314	SPC/GB02/037	United Kingdom		PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
0502314	C300095	Netherlands		PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
0503785	CA 2011 00026	Denmark		PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0454511	SPC/GB99/008	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015

Market Dynamics and Financial Trajectory for Trandate HCT

Last updated: March 23, 2026

What is Trandate HCT?

Trandate HCT combines labetalol hydrochloride and hydrochlorothiazide. It treats hypertension by lowering blood pressure through two mechanisms: labetalol blocks adrenergic receptors, decreasing adrenaline effects, while hydrochlorothiazide promotes diuresis. Approved primarily in the U.S. and Europe, it remains a niche antihypertensive therapy.

Market Size and Penetration

Current Market Size

The global antihypertensive drugs market was valued at approximately $31 billion in 2022, growing at a CAGR of 3.5% (Grand View Research, 2023)[1]. Trandate HCT's direct share comprises less than 0.5% due to the dominance of other classes like ACE inhibitors, ARBs, and calcium channel blockers.

Geographic Focus

• United States: Established market with stable demand.
• Europe: Moderate penetration; prescription patterns favor newer, branded agents.
• Emerging markets: Limited presence owing to cost constraints and patent status.

Off-Patent Status

Trandate HCT’s patent protection expired in the early 2000s. It is now manufactured as a generic, increasing price competition but reducing R&D incentives for reformulation.

Competitive Landscape

Major Competitors

• Brand Name Drugs: Norvasc (amlodipine), Lisinopril, Losartan.
• Generics: Multiple manufacturers produce labetalol HCT combinations.
• Newer Agents: Fixed-dose combinations with improved side effect profiles.

Market Position

Trandate HCT is positioned as a secondary or alternative therapy for patients intolerant to first-line agents. Its prescription volume in the U.S. remains steady but modest.

Regulatory Environment

• U.S.: Approved by FDA; marketed as generic.
• Europe: Approved by EMA, with general favor towards combination drugs.
• Upcoming Policies: Increased focus on combination therapies' safety profiles; regulatory approval is streamlined for generics.

Financial Trajectory

Revenue Trends

Estimated annual sales hover around $50 million globally, with the U.S. accounting for roughly 70% of revenue. Sales have been flat over the past five years, reflecting limited growth and market saturation.

Pricing and Reimbursement

• Price point: $1.50-$3.00 per tablet.
• Reimbursement: Typically covered under standard prescription drug plans.
• Cost competition: Intense, with multiple generics driving prices down.

R&D Investment and Innovation

Limited R&D efforts target reformulation or new indications, given the drug’s age and market saturation. Any innovation would face significant regulatory hurdles and low differentiation.

Market Risks and Opportunities

Risks

• Pricing Pressure: Entry of lower-cost generics caps revenue.
• Regulatory Changes: New safety standards could impact approval or renewals.
• Market Shift: Preference for newer agents with better side-effect profiles.

Opportunities

• Extended Indications: Potential for hypertension with comorbid conditions.
• Formulation Improvements: Approved once-daily formulations could improve adherence.
• Emerging Markets: Large population bases may offer growth if cost barriers are addressed.

Key Financial Metrics

Metric	2022 Estimate	Notes
Global Sales	~$50 million	Mostly from generic sales
U.S. Market Share	~70%	Due to established prescriber base
Unit Price	$1.50–$3.00	Per tablet, varies by manufacturer
Revenue Growth	0%–2% annually	Flat due to market saturation

Strategic Outlook

Given the drug’s entrenched generic status, minimal R&D, and competitive landscape, Trandate HCT’s market growth prospects are limited. Future revenue streams rely on expanding indications, formulations, or geographic outreach, especially in underpenetrated regions.

Key Takeaways

• Trandate HCT dominates as a generic antihypertensive in the U.S. but accounts for a small market share globally.
• Revenue has plateaued at approximately $50 million annually.
• Patent expiration and generic competition suppress pricing power.
• Market risks include pricing pressures and preference shifts towards newer agents.
• Opportunities exist in formulation optimization and emerging markets but require strategic investments.

FAQs

1. Is Trandate HCT still under patent protection?
No. Its patent expired during the early 2000s, making it a generic product.

2. What is the outlook for Trandate HCT’s sales?
Sales are expected to remain flat or decline slightly due to generic competition and market saturation.

3. Are there new formulations of Trandate HCT in development?
Currently, no significant reformulations are announced; newer formulations would face regulatory and market entry challenges.

4. How does Trandate HCT compare to other antihypertensives?
It is less favored than newer agents offering improved side-effect profiles or once-daily dosing, limiting its attractiveness.

5. What are the main growth opportunities?
Expansion into emerging markets or potential new indications could sustain modest growth if pursued strategically.

---

Citations

[1] Grand View Research. (2023). Antihypertensive Drugs Market Size, Share & Trends Analysis.